Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015


#502887

46pages

Global Markets Direct

$ 2000

In Stock

Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015, provides an overview of the Nonmelanomatous Skin Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonmelanomatous Skin Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Nonmelanomatous Skin Cancer - Overview 7
Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis 8
Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies 9
Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes 10
Nonmelanomatous Skin Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Nonmelanomatous Skin Cancer - Products under Development by Companies 14
Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes 15
Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development 16
Advancell 16
EcoBiotics Limited 17
Hexima Limited 18
LEO Pharma A/S 19
Spherium Biomed S.L. 20
Nonmelanomatous Skin Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles ANS-40 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ANS-401 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ANS-403 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
EBC-46 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OXT-328 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Peptide for Non-Melanoma Skin Cancer - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SP-12054 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccine for HPV Associated Skin Cancer - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Nonmelanomatous Skin Cancer - Recent Pipeline Updates 42
Nonmelanomatous Skin Cancer - Dormant Projects 43
Nonmelanomatous Skin Cancer - Discontinued Products 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Comparative Analysis by Unknown Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Nonmelanomatous Skin Cancer - Pipeline by Advancell, H2 2015 16
Nonmelanomatous Skin Cancer - Pipeline by EcoBiotics Limited, H2 2015 17
Nonmelanomatous Skin Cancer - Pipeline by Hexima Limited, H2 2015 18
Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H2 2015 19
Nonmelanomatous Skin Cancer - Pipeline by Spherium Biomed S.L., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H2 2015 42
Nonmelanomatous Skin Cancer - Dormant Projects, H2 2015 43
Nonmelanomatous Skin Cancer - Discontinued Products, H2 2015 44

List of Figures
Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Targets, H2 2015 22
Number of Products by Stage and Targets, H2 2015 22
Number of Products by Mechanism of Actions, H2 2015 24
Number of Products by Stage and Mechanism of Actions, H2 2015 24
Number of Products by Routes of Administration, H2 2015 26
Number of Products by Stage and Routes of Administration, H2 2015 26
Number of Products by Molecule Types, H2 2015 28
Number of Products by Stage and Molecule Types, H2 2015 28